<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766480</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000615602</org_study_id>
    <secondary_id>TOYAMAU-TRIEC0601</secondary_id>
    <nct_id>NCT00766480</nct_id>
  </id_info>
  <brief_title>Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus</brief_title>
  <official_title>An Investigational Study of Chemoradiosensitivity Prediction With Genetic Profiling of Esophageal Biopsy for Squamous Cell Carcinoma of the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toyama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may
      help doctors learn more about changes that occur in DNA and identify biomarkers related to
      cancer. It may also help doctors predict how patients will respond to treatment.

      PURPOSE: This clinical trial is studying tissue samples in predicting how well chemotherapy
      and radiation therapy will kill cancer cells in patients with squamous cell carcinoma of the
      esophagus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To search for chemoradiosensitivity-related genes using a pre-treatment biopsy sample in
           patients with esophageal squamous cell carcinoma treated with cisplatin, fluorouracil,
           and concurrent radiotherapy.

        -  To establish an algorithm for prediction of chemoradiosensitivity in these patients.

      OUTLINE: Patients receive 1 of the following treatment regimens:

        -  Regimen 1: Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose
           fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on
           days 1-4 and 29-32. Patients undergo salvage surgery if needed.

        -  Regimen 2: Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose
           fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and
           salvage surgery as in regimen 1.

      Pre-operative biopsy samples are analyzed by DNA microarray chip to establish an algorithm
      for prediction of chemoradiosensitivity.

      After completion of study therapy, patients are followed at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year local progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete histological response</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo radiotherapy</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the thoracic esophagus

               -  Stage IIA, IIB, or III (except T4) disease

               -  Tumor diameter &lt; 8 cm

          -  No tumor extension to the cervical esophagus or cardia of the stomach

          -  No multiple and different histological types of cancer

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC ≥ 4,000/mm³

          -  Absolute neutrophil count ≥ 2,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL

          -  AST and ALT ≤ 100 IU/L

          -  Total serum bilirubin ≤ 1.5 mg/dL

          -  Creatinine ≤ 1.2 mg/dL

          -  Creatinine clearance ≥ 60mL/min

          -  SpO_2 (room air) ≥ 95%

          -  Not pregnant or nursing

          -  No abnormal ECG findings requiring treatment

          -  No interstitial pneumonitis or no pulmonary fibrosis

          -  No severe complication (e.g., heart failure, renal failure, hepatic failure, or
             uncontrollable diabetes mellitus)

          -  No collagen disease (e.g., PSS or dermatomyositis)

          -  No mental disease

          -  No active bacterial infection

          -  No virus infection (i.e., HBV, HCV, PTHA, or HIV)

        PRIOR CONCURRENT THERAPY:

          -  No prior surgery for esophageal cancer

          -  No prior chemotherapy

          -  No prior chest radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Shimada, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toyama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunzo Hatooka</last_name>
      <phone>81-52-762-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiko Minashi</last_name>
      <phone>81-4-7133-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University School of Medicine</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiaki Tanaka</last_name>
      <phone>81-942-35-3311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gunma University Graduate School of Medicine</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Kuwano, MD, PhD</last_name>
      <phone>81-27-220-8224</phone>
      <email>hkuwano@med.gunma-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koushi Oh</last_name>
      <phone>81-798-45-6582</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichiro Ikeda</last_name>
      <phone>81-19-651-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>701-01</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshihiro Hirai</last_name>
      <phone>81-86-462-1199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Graduate School of Medical Science at the University of Ryukyu</name>
      <address>
        <city>Nishiharacho</city>
        <state>Okinawa</state>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadashi Nishimaki</last_name>
      <phone>81-98-895-3331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinki University School of Medicine</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takushi Yasuda</last_name>
      <phone>81-72-366-0221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Graduate School of Medicine</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaichi Ohira</last_name>
      <phone>81-6-6645-3837</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasushi Toh, MD, PhD</last_name>
      <phone>81-92-541-3231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Asa Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>731-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidenori Mukaida</last_name>
      <phone>81-82-815-5211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagoshima University</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shoji Natsugoe</last_name>
      <phone>81-99-275-5361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michihide Mitsumori</last_name>
      <phone>81-75-751-3417</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuo Kanda, MD</last_name>
      <phone>81-25-227-2228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Yabusaki</last_name>
      <phone>81-25-266-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryu Ishihara</last_name>
      <phone>81-6-6972-1181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mita Hospital at the International University of Health and Welfare</name>
      <address>
        <city>Tokyo</city>
        <zip>108-8329</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken-ichi Mafune, MD</last_name>
      <phone>81-3-3451-8121</phone>
      <email>mafune@iuhw.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsutomu Nakamura</last_name>
      <phone>81-3-3353-8111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyama University Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>930-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutaka Shimada, MD, PhD</last_name>
      <phone>81-76-434-7331</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage IIA esophageal cancer</keyword>
  <keyword>stage IIB esophageal cancer</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

